BioSpace News Archive

Vivera Pharmaceuticals, in partnership with Burkhan Group, is excited to announce a new testing initiative in Southern California.

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.

NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy, today announced that it has received an Orphan drug designation from FDA for gene therapy-based treatment of Stargardt disease, a form of inherited retinal degenerative disease caused by gene mutation and passed on to children.

ChoiceSpine LLC, a privately held spinal device manufacturer based in Knoxville, TN, announced today that the Food and Drug Administration (FDA) has provided additional 510(k) clearance to the Tiger Shark Cervical Spacer System.

The study conducted by a group of researchers at the James B. Edwards College of Dental Medicine at the Medical University of South Carolina showed that the Aegis VacStation, a chair-side extra-oral suction device from the CAO Group Inc., can effectively eliminate 100% of spatter and 99.8% of aerosol generated by high-speed dental procedures.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will hold a conference call today, Monday, January 25 at 4:30 pm ET on the Company’s announcement that results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2.

Aerobiotix, Inc., a leading manufacturer of air treatment devices for hospitals and healthcare, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Aerocure-MD medical air purification system

Epilepsy research in North America has received a major boost. Epilepsy Canada, headquartered in Toronto and CURE Epilepsy, based in Chicago, two organizations at the forefront of funding scientific research, have agreed to form a strategic working relationship which formally commenced on January 1, 2021.

bitBiome, Inc. (Representative Director: Sunao Fujioka, “bitBiome”) and Fred Hutchinson Cancer Research Center (Professor: David Fredricks, “Fred Hutch”) have developed a collaborative research agreement on the analysis of the vaginal microbiome related to the Bacterial Vaginosis on November 26th , 2020.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,250,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.25 per ADS for gross proceeds of approximately $6.56 million.